RxDoctor Payments Data

Kelly Kane, MD

Dermatopathology · Somers Point, NJNPI 1497776579

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.3% of the total across 116 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 22.1% — the pattern of someone who eats at a lot of different presentations.

$1,934in general payments, 2019–2025

Across 116 payments — averaging $16.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$428
  • Sanofi$196
  • Sun Pharmaceutical Industries Inc.$174
  • Pfizer$128
  • Novartis$121
  • Johnson & Johnson$117
  • plus $770 from 19 others

What the payments were for

  • Food & beverage$1,92099%
  • Education$141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few dermatopathology providers in New Jerseyto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$1,454,517
Medicare patients
1,212
Services billed
47,800

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OtezlaApremilast35$208,031
Doxycycline Ir-DrDoxycycline Monohydrate20$11,736
Ivermectin20$6,600
Fluorouracil85$4,564
Ketoconazole165$3,826
Metronidazole70$2,863
Triamcinolone Acetonide116$1,768
Tacrolimus13$1,154
Clindamycin Phosphate21$1,098
Clobetasol Propionate41$1,051
Azelaic Acid25$990
Tretinoin28$979
Fluocinolone Acetonide Oil17$642
Doxycycline Hyclate39$642
ValacyclovirValacyclovir Hcl50$610

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$29$208,03135 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few dermatopathology providers in New Jerseyon file to place this against a meaningful peer group, so we don't.

Other dermatopathology in Somers Point

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →